ICOS to Participate in Upcoming Healthcare Conference.Business Editors/Health/Medical Writers BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 22, 2003 ICOS Corporation (Nasdaq:ICOS) announced today that it will participate in the JPMorgan Healthcare Conference on January 13, 2004.
JPMorgan Healthcare Conference Presentation
Date: January 13, 2004
Time: 11:00 a.m. EST
Speaker: Paul N. Clark, Chairman, CEO and President
A webcast of this ICOS presentation will be available in
real-time and a replay will be available through January 20,
2004. The webcast can be accessed through the ICOS website,
www.icos.com, Investor - Events section.
Additional information on ICOS, including past press releases, is available at www.icos.com. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology Structural biology is a branch of molecular biology concerned with the study of the architecture and shape of biological macromolecules—proteins and nucleic acids in particular—and what causes them to have the structures they have. , high throughput drug screening, medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. and gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. and other urologic disorders urologic disorder Any condition affecting the kidneys, often understood to be of the collecting tubules and southward. Cf Kidney disease. , and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing opportunities to market breakthrough products. The forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. contained in this press release represent ICOS' judgment as of the date of this release. ICOS undertakes no obligation to publicly update any forward-looking statements. The biotechnology and pharmaceutical businesses are risky and there can be no assurance that any particular product candidate will progress and become a commercial product. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion